| 前收盘价格 | 9.49 |
| 收盘价格 | 9.77 |
| 成交量 | 323,462 |
| 平均成交量 (3个月) | 4,764,126 |
| 市值 | 85,286,656 |
| 股市价格/股市净资产 (P/B) | 2.10 |
| 52周波幅 | |
| 利润日期 | 12 May 2025 - 16 May 2025 |
| 营业毛利率 | -167.29% |
| 营业利益率 (TTM) | -334.91% |
| 稀释每股收益 (EPS TTM) | -2.02 |
| 季度收入增长率 (YOY) | -13.20% |
| 流动比率 (MRQ) | 11.11 |
| 营业现金流 (OCF TTM) | -16.53 M |
| 杠杆自由现金流 (LFCF TTM) | -10.69 M |
| 资产报酬率 (ROA TTM) | -42.95% |
| 股东权益报酬率 (ROE TTM) | -69.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | CervoMed Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-1.0
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -3.0 |
| 平均 | -1.00 |
|
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.38% |
| 机构持股比例 | 17.22% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Cornerstone Wealth Management, Llc | 31 Dec 2024 | 20,650 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 21.00 (Canaccord Genuity, 114.29%) | 购买 |
| 中 | 15.00 (53.06%) | |
| 低 | 10.00 (D. Boral Capital, 2.04%) | 购买 |
| 平均值 | 16.00 (63.27%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 8.30 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 26 Mar 2025 | 10.00 (2.04%) | 购买 | 7.71 |
| 17 Mar 2025 | 10.00 (2.04%) | 购买 | 9.05 | |
| Canaccord Genuity | 18 Mar 2025 | 21.00 (114.29%) | 购买 | 9.34 |
| Chardan Capital | 18 Mar 2025 | 14.00 (42.86%) | 购买 | 9.34 |
| 13 Mar 2025 | 14.00 (42.86%) | 购买 | 5.79 | |
| Roth MKM | 18 Mar 2025 | 20.00 (104.08%) | 购买 | 9.34 |
| 11 Mar 2025 | 15.00 (53.06%) | 购买 | 2.36 | |
| Jones Trading | 13 Mar 2025 | 15.00 (53.06%) | 购买 | 5.79 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合